Navidea Biopharmaceuticals Schedules Third Quarter 2017 Earnings Conference Call and Business Update
October 31 2017 - 5:53PM
Business Wire
Conference call to take place Wednesday,
November 8, 2017 at 8:30am E.T.
Navidea Biopharmaceuticals (NYSE MKT: NAVB) (“Navidea” or “the
Company”), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, today
announced it will host a conference call on Wednesday, November 8,
2017 at 8:30am E.T. to discuss its financial results for the third
quarter 2017, in conjunction with the filing of its quarterly
report on Form 10-Q for the third quarter ended September 30,
2017.
Michael Goldberg, President and Chief Executive Officer, and Jed
Latkin, Chief Financial and Operating Officer of Navidea, will host
the call and provide an update on recent developments and clinical
progress. Management will be answering questions live immediately
following the call.
To participate in the call, please dial 1-866-548-4713
(toll-free) in the U.S. and Canada. The conference ID number is
6714834.
Event: Q3 2017 Earnings and Business Update
Conference Call
Date: Wednesday, November 8, 2017
Time: 8:30am (Eastern Time)
U.S. & Canada
Dial-in: 1-866-548-4713 (toll free)
Conference ID:
6714834
A live audio webcast of the conference call will also be
available on the investor relations page of Navidea’s corporate
website at www.navidea.com. In addition, the recorded conference
call can be replayed and will be available for 90 days following
the call on Navidea’s website.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the
sites and pathways of disease and enable better diagnostic
accuracy, clinical decision-making, and targeted treatment.
Navidea’s Manocept platform is predicated on the ability to
specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the
molecular backbone of Tc 99m tilmanocept, the first product
developed and commercialized by Navidea based on the platform. The
development activities of the Manocept immunotherapeutic platform
are being conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver
superior growth and shareholder return by bringing to market novel
products and advancing the Company’s pipeline through global
partnering and commercialization efforts.
For more information, please visit www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171031006633/en/
Navidea Biopharmaceuticals, Inc.Jed Latkin, CFO/COO,
614-551-3416jlatkin@navidea.comorEdison AdvisorsTirth Patel,
646-653-7035tpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024